{"id":1857,"date":"2026-09-05T06:00:00","date_gmt":"2026-09-05T06:00:00","guid":{"rendered":"https:\/\/www.comforcare.com\/north-san-diego\/?p=1857"},"modified":"2026-09-03T19:47:01","modified_gmt":"2026-09-03T19:47:01","slug":"levodopa-parkinsons-disease-research","status":"publish","type":"post","link":"https:\/\/www.comforcare.com\/north-san-diego\/resources\/blog\/levodopa-parkinsons-disease-research\/","title":{"rendered":"New Parkinson’s Drug Research: How to Understand Preclinical Results"},"content":{"rendered":"\n

Why Levodopa Research Continues<\/strong><\/p>\n\n\n\n

Levodopa is one of the main treatments for Parkinson\u2019s disease. The brain uses levodopa to make dopamine, which can help improve movement symptoms.<\/p>\n\n\n\n

For many people, levodopa works well. Over time, however, its effects may become less predictable. Some people also develop dyskinesia<\/strong>, or involuntary movements that can make everyday activities less comfortable or more difficult.<\/p>\n\n\n\n

On August 11, 2026, the National Institutes of Health (NIH) highlighted research into a new drug candidate that may help preserve levodopa\u2019s benefits while reducing dyskinesia. The original study was published in Science Translational Medicine<\/em> on July 15, 2026.<\/p>\n\n\n\n

The findings are encouraging, but there is an important limitation: the research is still in the preclinical stage.<\/strong> The results do not show that the drug is safe or effective for people<\/p>\n\n\n\n

What the Researchers Found<\/strong><\/p>\n\n\n\n

Researchers looked at how levodopa changes gene activity in brain cells that respond to dopamine. They found some changes that appeared to be linked to improved movement, while others were associated with dyskinesia.<\/p>\n\n\n\n

The researchers then searched for compounds that might encourage the helpful changes while reducing the changes linked to dyskinesia.<\/p>\n\n\n\n

This led them to a compound called SB-0107<\/strong>.<\/p>\n\n\n\n

In rodent models of Parkinson\u2019s disease, adding SB-0107 to levodopa improved movement benefits without causing or worsening dyskinesia in the same way. Researchers then tested the combination in a nonhuman primate model, where NIH reported similar improvements in levodopa\u2019s effects and reductions in dyskinesia.<\/p>\n\n\n\n

The team later modified the compound so it could remain in the body longer. One version, SB-0110<\/strong>, is now being developed as a possible candidate for future human trials.<\/p>\n\n\n\n

Why Animal Studies Are Only the Beginning<\/strong><\/p>\n\n\n\n

Animal studies are an important part of drug research. They help scientists understand how a potential treatment works and whether it is worth studying further.<\/p>\n\n\n\n

But what happens in an animal does not always happen the same way in people.<\/p>\n\n\n\n

A drug may be absorbed differently, cause unexpected side effects, interact with other medications, or simply not provide the same benefits in humans.<\/p>\n\n\n\n

That is why potential treatments must go through carefully designed clinical trials before they can become available. These trials look at safety, dosage, side effects and whether the treatment actually works.<\/p>\n\n\n\n

NIH reported that the research team hopes to begin human trials next year. However, research plans and timelines can change. Until human trial results are available, it is too early to make claims about benefits for people with Parkinson\u2019s.<\/p>\n\n\n\n

People living with Parkinson\u2019s should not seek out this compound outside of a legitimate clinical trial or change their medications because of this research<\/strong>. Changes such as wearing-off periods, dyskinesia, dizziness, hallucinations, excessive sleepiness, or other new symptoms should be discussed with the prescribing clinician.<\/p>\n\n\n\n

Make Medical Appointments More Useful<\/strong><\/p>\n\n\n\n

Research like this can also be a good reminder to pay attention to patterns in daily life.<\/p>\n\n\n\n

Consider keeping a simple record of:<\/p>\n\n\n\n